Journal
JOURNAL OF MOLECULAR CELL BIOLOGY
Volume 5, Issue 3, Pages 207-209Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jmcb/mjt009
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA127483, R01 CA109322, R01 CA140243] Funding Source: Medline
- NIAID NIH HHS [T32 AI078892] Funding Source: Medline
Ask authors/readers for more resources
Myeloid-derived suppressor cells (MDSC) have recently emerged as one of the central regulators of the immune system. In recent years, interest in understanding MDSC biology and applying MDSC for therapeutic purpose has exploded exponentially. Despite recent progress in MDSC biology, the mechanisms underlying MDSC development from expansion and activation to polarization in different diseases remain poorly understood. More recent studies have demonstrated that two MDSC subsets, M (monocytic)-MDSC and G (granulocytic)-MDSC, are able to polarize from a classically activated phenotype (M1) to an alternatively activated one (M2), or vice versa, in tumor-bearing mice. This phenotypic polarization affects MDSC function and disease progression. In this article, we summarize and discuss polarization, mechanism and therapeutic potential of MDSC. An emphasis is placed on the emerging concept of reprogramming MDSC polarization as a therapeutic strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available